Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.

Rev Assoc Med Bras (1992) · 2026 · PMC13035191 · PMID 41919885

Europe PMC DOI

hedged sentences

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

showed a trendp=0.098so close (0.05 < p ≤ 0.1)

Liver metastasis showed a trend toward shorter PFS (HR 0.790; 95%CI 0.578–1.079; p=0.098), whereas MMR deficiency demonstrated a borderline association (HR 0.762; 95%CI 0.525–1.106; p=0.174).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Consistently, the difference in overall survival between the groups did not reach statistical significance, and Cox regression analysis likewise did not demonstrate a significant association between TP53 mutations and OS (HR 0.681; 95%CI 0.411–1.127; p=0.116).

also in 111,027 other papers

a numerical trendno p-value reported

The absence of a statistically significant association with OS, despite a numerical trend, may reflect the influence of additional clinical factors or subsequent lines of therapy that mitigate the long-term impact of TP53 status.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.